Copy number alterations in a matched pair of benign epithelial and prostate cancer cell lines derived from the same patient were assessed using array-based comparative genomic hybridisation (aCGH). The cancer cell line showed a gain of chromosome 7, deletion of chromosome 8, gains (including high level) and losses on chromosome 11, loss of 18p and gain of 20q. Deletions on chromosome 8 were confirmed with microsatellite markers. The aCGH results were compared to gene expression data obtained using DNA microarrays and suggested the involvement of caspases and ICEBERG on 11q and E2F1 on chromosome 20q.
Introduction
The genetic changes underlying the development and progression of prostate cancer are poorly understood. Comparative genomic hybridisation (CGH) has been used to look for amplification and loss of DNA in many types of cancer, including prostate cancer. [1] [2] [3] The sequencing of the human genome and the creation of genome maps have facilitated the development of arraybased comparative genomic hybridisation (aCGH), a more sensitive alternative to conventional CGH. This technique has been used to identify regions of complete genetic loss and to characterise copy number changes in prostate cancer cell lines. 4, 5 In aCGH, instead of hybridising labelled DNA to a chromosome spread, the DNA is hybridised to slides spotted with arrays of cDNA clones, oligonucleotides, bacterial artificial chromosome (BAC), P1 artificial chromosome (PAC) or yeast artificial chromosome (YAC) clones. The advantage of aCGH over conventional metaphase CGH is that aCGH gives a much higher resolution of closely spaced aberrations and allows linking of ratio changes to genomic/genetic markers. 6 It is also able to map the copy number alterations to a small region on the chromosome and hence the positions of putative tumour suppressor and oncogenic loci. Array CGH allows highthroughput analysis of chromosomal alterations and will be useful in profiling archival tumours. It is also well suited to the study of cancer cells as it is relatively insensitive to contamination from normal cell DNA. 7 We have used a 1 Mb spaced BAC array 8 printed at The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK, to identify changes found in a prostate cancer cell line. This analysis will enable us to refine the boundaries of known regions of copy number change. A benign prostate epithelial cell line, 1542 NP 2 Tx (NP 2 Tx), and a prostate cancer cell line, 1542 CP 3 Tx (CP 3 Tx), were analysed for gross chromosomal changes. These cell lines, derived from the same patient, were established by immortalisation with the E6 and E7 proteins of human papilloma virus serotype 16. 9 Such paired cell lines represent a valuable system for the study of genetic changes occurring during prostate cancer development and/or progression. The use of the cell lines removes the possible problems associated with normal DNA contamination and permitted assessment of the aCGH platform for future analysis of prostate tumours. Applied to clinical samples, aCGH could be used for profiling prostate tumours, predicting disease outcome and possibly tailoring patient treatment.
Experimental procedures
Cell culture and DNA extraction
The benign prostate epithelial cell line, 1542 NP 2 Tx (NP 2 Tx), and the prostate cancer cell line, 1542 CP 3 Tx (CP 3 Tx), were maintained as originally described, 9 in keratinocyte serum-free medium (Invitrogen, Paisley, UK) supplemented with 5% FBS in a 5% CO 2 humidified incubator at 36.51C. Cells were harvested by trypsinisation and washed in PBS, and DNA was extracted using the DNeasy Tissue Kit (Qiagen, Sussex, UK) according to the manufacturer's instructions.
Array hybridisation and analysis
Genomic DNA was labelled using the Bioprime labelling kit (Invitrogen). Briefly, 1 mg of DNA in a volume of 21 ml dH 2 O and 20 ml of random primers was denatured for 5 min at 951C and immediately placed on ice for 10 min. A total of 5 ml of dNTP mix (12 ml dATP (100 nM), 12 ml dGTP (100 nM), 12 ml dTTP (100 nM) and 6 ml dCTP (100 nM); Invitrogen), 3 ml of Fluorolink Cy3-dCTP or Fluorolink Cy5-dCTP (Amersham Biosciences, UK) and 1 ml Klenow (Invitrogen) were added and incubated overnight at 371C. Experiments were performed in triplicate, with three independent cell cultures and in dye swap; so DNA from CP 3 Tx cells labelled with Cy3 was hybridised against DNA from NP 2 Tx cells (used as a reference) labelled with Cy5 and vice versa. The dye swap was also carried out for cell line DNA hybridised against a general reference DNA isolated from pooled peripheral blood samples taken from female subjects (Breakthrough). Each reaction was purified using the MinElute Purification Kit (Qiagen) following the manufacturer's instructions. Labelled NP 2 Tx and CP 3 Tx, or cell line and reference DNA, were then combined and precipitated with 100 ml of human Cot-1 DNA (1 mg/ml, Invitrogen), 12 ml 3 M sodium acetate pH 7.0 and 300 ml ice-cold 100% ethanol for 1 h at À201C. The samples were centrifuged at maximum speed for 30 min in a microcentrifuge to collect the pellets. The pellets were washed in 500 ml 70% ethanol and dried in the dark at room temperature for approximately 15 min. Samples were incubated in the dark at room temperature for 30-45 min in 120 ml hybridisation buffer (50% deionised formamide, 10% dextran sulphate, 2 Â SSC, 2% SDS, 4 mg/ml yeast tRNA) and vortexed. The solubilised samples were denatured at 701C for 15 min and re-annealed at 371C for 30 min.
The arrays used comprised 5800 BAC clones spanning the genome at B1 Mb resolution (Breakthrough). Prior to hybridization, the arrays were incubated at 421C for 45 min in pre-hybridisation buffer (25% deionised formamide, 5% SSC, 5% SDS, 1% BSA), rinsed in dH 2 O and dried by centrifuging at 1000 g. The samples were applied to the arrays, covered with 22 Â 60 mm coverslips and incubated overnight at 421C in a dark humidified slide chamber.
Arrays were gently dipped into and out of Solution 1 (5% SSC, 0.1% SDS) to remove the coverslips and then washed in Solution 1 at 451C for 15 min. They were then washed twice in Solution 2 (50% deionised formamide, 2% SDS) at 451C for 15 min, followed by successive washes in Solution 3 (5% SSC, 0.1% SDS) for 30 min at 451C and Solution 4 (0.2% SSC) for 15 min at room temperature. The arrays were dried by centrifuging at 1000 g for 2 min and then scanned using a GenePix 4000B scanner (Axon Instruments, CA, USA) and the images processed with GenePix 5.2 (Axon Instruments). Poorly hybridised clones, identified by visual inspection, were rejected and removed from further analysis. The median localised background signal for each clone was subtracted and each clone Cy5/Cy3 ratio subjected to printTip Loess normalisation. All data transformation and statistical analyses were carried out in R 2.0.1 (http://www.r-project.org/). Other programs, aCGH Smooth 10 and CGH Analyzer, 8 were used for graphical presentation of the results. The threshold for deletions was set at 0.85, and that for gains at 1.15. Primary aCGH data have been made publicly available (ArrayExpress).
Loss of heterozygosity analysis
DNA samples from the benign and cancer cell lines were amplified by polymerase chain reaction (PCR) using HEX-or FAM-labelled primers for the following four microsatellite markers: D8S131 (Invitrogen), NEFL, D8S136, D8S1134 (Research Genetics). These markers were chosen because they are located within regions that were deleted in the CP 3 Tx cell line according to aCGH. Each PCR reaction contained 2 ml genomic DNA, 7.5 ml Easy PCR mix (Qiagen), 8 mM of each primer and dH 2 O up to a final volume of 15 ml. Amplification was carried out in a thermal cycler with one cycle at 951C for 15 min; 60 cycles of amplification at 951C for 45 s, 541C for 45 s, 741C for 45 s; and a final extension at 741C for 7 min. The PCR products were diluted appropriately in dH 2 O and 2 ml of each was added to 8 ml of a mixture of HIDI and ROX (Applied Biosystems, UK). Samples were denatured for 5 min at 951C prior to automated fluorescent DNA sequencing (model 3700 sequencer, Applied Biosystems). The band pattern was analysed using standard software (GeneScan, Perkin Elmer, UK) and compared between benign and cancer DNA. LOH was defined when at least 50% loss of one allele was observed in the cancer cells compared to the matched normal cells. LOH was confirmed in three independent experiments.
Gene expression microarrays (Genechip Oligoarray)
Total RNA from three independent cell cultures of 1542 CP 3 Tx and 1542 NP 2 Tx cells was isolated using TRIzolt (Invitrogen). cDNA was prepared from 5 mg RNA using the SuperScriptt Double-Stranded cDNA Synthesis kit (Invitrogen) and T7-(dT) 24 primer (Genset Corp., USA). Biotinylated cRNA was synthesised from cDNA using The images were analysed using Microarray Suite v.5.0 and Data Mining Tool Software (Affymetrix). Data sets were standardised by global scaling of the average fluorescent intensities of all probe sets to a constant target value of 500 for all arrays. Using Microarray Suite, a change probability value, difference call and signal log ratio were calculated for comparison of two chips (one pair) used for 1542 NP 2 Tx and 1542 CP 3 Tx. Nine such pairwise comparisons were performed using RNA isolated from three samples of 1542 NP 2 Tx and three samples of 1542 CP 3 Tx. A gene was considered differentially expressed based on the following criteria: (1) a change in probability value o0.003 (increased expression) or 40.997 (decreased expression); (2) an increase or decrease in at least six of nine paired comparisons; and (3) an average signal log ratio in nine paired comparisons of 41 (42-fold increase) or o1 (42-fold decrease).
Results

Array comparative genomic hybridisation
Array CGH was used to identify regions of chromosomal loss and gain in the cancer cell line, 1542 CP 3 Tx, in comparison to the benign cell line, 1542 NP 2 Tx, derived from the same patient, and also in CP 3 Tx and NP 2 Tx compared to pooled normal female DNA from peripheral blood. Normal female DNA was used to provide an internal control for the aCGH-the loss of a copy of chromosome X. Data were analysed using the aCGH Smooth 10 and CGH Analyzer 8 software, and an overview of the changes in the entire genome is shown in Figure 1 .
CP 3 Tx showed a gain of chromosome 7 and a deletion of chromosome 8 when compared to NP 2 Tx (Figure 2 ; Table 1 ). On chromosome 11, there was a deletion of q13.1-q14.1 and a gain of q14.3-22.3, with a high-level gain at q22.3 ( Figure 3 ; Table 1 ). There was also a deletion of 18p (Figure 4 ; Table 1 ) and a gain of 20q13.33 ( Figure 5 ; Table 1 ).
Hybridisation of NP 2 Tx against the normal reference DNA showed that there were copy number alterations in the benign prostate epithelial cell line. Gains of 8q ( Figure 2; Table 1 ), 11q13.1-11q22.3 ( Figure 3 ; Table 1 ), 18p11.31-18p11.21 ( Figure 4 ; Table 1 ) and 20q13.33 ( Figure 5 ; Table 1 ) were identified in the cell line, together with a deletion of 11q beyond q22.3 ( Figure 3 ; Table 1 ).
CP 3 Tx showed a deletion of 8p when hybridised against the normal reference DNA (Figure 2 ; Table 1 ). In chromosome 11, which had several chromosomal alterations, there was a gain of 11q12.1-11q22.3, with a high-level gain of 11q14.3-11q22.3, and a deletion of 11q22.3-11q25 ( Figure 3 ; Table 1 ). There was a gain of 20q11.21-20q13.33 with a high-level gain at 20q13.33 ( Figure 5 ; Table 1 ).
Loss of heterozygosity
Analysis of microsatellite markers situated within chromosome 8 was performed to confirm the aCGH results. Four markers on chromosome 8 were chosen, and LOH was found in CP 3 Tx for all four with the complete loss of one allele in CP 3 Tx compared to NP 2 Tx. The LOH results are summarised in Table 2 .
Gene expression microarray
The array CGH results were compared with gene expression data obtained using an Affymetrix HU133A microarray with RNA samples extracted from the paired cell lines 1542 NP 2 Tx and 1542 CP 3 Tx. A 3 Â 3 matrix analysis utilising the DNA Mining Tool (Affymetrix) was first used to compare the gene expression of three independent 1542 CP 3 Tx cultures to three of 1542 NP 2 Tx, resulting in nine comparisons.
A total of 27 genes on chromosome 8, including N33 and MTUS1, were downregulated at the mRNA expression level in the 1542 CP 3 Tx cell line compared to the 1542 NP 2 Tx cell line. CASP1, CASP4 and CASP5, which are located on 11q22.3, a region with high-level gains in CP 3 Tx, were found to be upregulated on the gene expression microarrays by at least two-fold. E2F1, a gene located on 20q11.2, was five-fold upregulated.
Discussion
Array CGH was used to investigate regions of chromosomal imbalance in the prostate cancer cell line, 1542 CP 3 Tx, and the benign prostate epithelial cell line, 1542 NP 2 Tx, derived from the same patient.
We identified a deletion of chromosome 8 in the cancer cell line. However, hybridisation of DNA from the two prostate cell lines against DNA from normal peripheral blood revealed that there was actually a gain of 8q in 1542 NP 2 Tx and a loss of 8p in 1542 CP 3 Tx. The formation of isochromosome 8q [i(8q)] in this prostate cancer cell line has previously been reported. 11 However, our results suggest that i(8q) is present in the benign prostate cell line and chromosome 8 is then lost in the cancer cell line, explaining the observed loss of 8p in the cancer cell line. Many known and putative tumour suppressor genes occur on 8p. The gene N33 on 8p22 is a candidate tumour suppressor gene located within a homozygously deleted region of metastatic prostate cancer. 12 Another gene on 8p22, MTUS1, encodes for multiple transcript variants, one of which is a mitochondrial protein that acts as a tumour suppressor. 13 Also of interest is NKX3-1, located on 8p21.2, which in a recent study showed loss of heterozygosity in more than half of the prostate cancers examined.
14 This gene was thought to function as a tumour suppressor, but its role in prostate cancer progression has recently been suggested to be regulatory. 15 The gene MSR1 on 8p22 has also been implicated in prostate cancer, but studies on this gene have been limited to the investigation of the effects of germline mutations with conflicting results. 16, 17 Microsatellite markers were used to confirm some of the alterations observed in chromosome 8. Four markers were chosen from chromosome 8, which was found to be Genetic changes in prostate cancer cells N Brookman-Amissah et al deleted according to aCGH. All the markers examined showed the complete loss of one allele in the cancer cell line, in accordance with the aCGH results. In addition, Affymetrix microarray data showed downregulation of 27 genes on chromosome 8 in the cancer cell line. This could be due to the deletion of a copy of chromosome 8 in the cancer cell line. The failure to detect a general downregulation of all genes on chromosome 8 could be due to the different regulatory mechanisms of expression of various genes. But these results, showing LOH in three markers on 8p and one on 8q, are consistent with a one copy loss of chromosome 8.
There was a gain of part of 11q in CP 3 Tx compared to NP 2 Tx. Hybridisation of both cell lines against the normal peripheral blood DNA, however, showed that there were gains in both cell lines in large portions of 11q, with mainly higher level gains of 11q22.3 in the cancer cell line than in the benign cell line. This resulted in a net gain in CP 3 Tx compared to NP 2 Tx. Genes in this region include CASP1, CASP4, CASP5 and ICEBERG. The caspases are known to induce apoptosis, [18] [19] [20] their sequential activation playing a central role in the execution phase, and the gene expression microarray data showed upregulation of all three. ICEBERG, a 21 is not present on the HU133A oligoarray. It would be interesting to know how its expression changes in the two cell lines. Downregulation or no change of ICEBERG expression, with a concomitant upregulation of these caspases, would be consistent with reports of an increased apoptotic rate in hormoneresponsive prostate cancer and in prostate cancer at the onset of hormone resistance (reviewed in Quinn et al 22 ) and requires further investigation. Cell regulation-related genes, CCND1 and EMSY on 11q13.3 and 11q13.5, respectively, are located on independently gained regions of chromosome 11, which showed a net loss in the cancer cell line. Further investigation of the relevance of this observation is also necessary.
The whole of chromosome 20 beyond 20q11.2 was gained in the CP 3 Tx cell line. Genes in this region include E2F1, a transcription factor on 20q11.2, which has recently been shown to be a positive transcriptional regulator of COX-2.
23 COX-2 promotes prostate tumorigenesis in animal models 24 and elevated expression of this gene has been observed in a transgenic mouse model of prostate cancer. 25 The benign and cancer cell lines were derived from the same patient and were immortalised using HPV16 E6 and E7 transforming proteins. While it is possible that genomic changes occurring as a result of either immortalisation or adaptation to cell culture may differ between the two cell lines, we assumed that most of these changes would be similar and would therefore not appear as differences between the two cell lines. Hybridising the cell lines to normal DNA from peripheral blood revealed chromosomal alterations in NP 2 Tx Array CGH has been shown to be a sensitive technique for detecting chromosomal alterations in these matched prostate cell lines. The arrays used cover the entire human genome at a 1 Mb resolution, and showed complex chromosomal alterations on chromosome 11, with a high-level gain at 11q22.3. Expression microarrays revealed a corresponding upregulation of caspases, which are involved in apoptosis. aCGH also showed a gain of the q-arm of chromosome 20 in the cancer cell line CP 3 Genetic changes in prostate cancer cells N Brookman-Amissah et al common normal reference DNA in studies of this kind. The use of more sensitive 'tiling path' arrays, which cover the genome at a much higher resolution, and hence map alterations to more discrete regions, 26 will enable better identification of chromosomal changes that are critical for the onset of prostate cancer and its progression, profiling of prostate tumours, and the eventual possible identification of markers associated with the outcome of treatment. Genetic changes in prostate cancer cells N Brookman-Amissah et al
